Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences (Nasdaq: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in three upcoming healthcare conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (September 3-5), the Stifel Virtual Immunology and Inflammation Forum (September 15-16), and the 11th Annual World Medical Innovation Forum (September 15-17). Management will conduct fireside chats and participate in a panel discussion on immunology, while also hosting one-on-one investor meetings.
Webcasts of the Cantor and Stifel fireside chats will be available on Jade's website with 90-day replay access.
Jade Biosciences (Nasdaq: JBIO), una società biotecnologica specializzata in terapie per le malattie autoimmuni, ha annunciato la sua partecipazione a tre conferenze sanitarie previste per settembre 2025.
L'azienda sarà presente al Cantor Global Healthcare Conference (3-5 settembre), al Stifel Virtual Immunology and Inflammation Forum (15-16 settembre) e al 11th Annual World Medical Innovation Forum (15-17 settembre). La direzione terrà sessioni informali (fireside chats), parteciperà a un panel sull'immunologia e organizzerà incontri individuali con gli investitori.
I webcast delle fireside chat del Cantor e dello Stifel saranno disponibili sul sito di Jade con accesso alla replica per 90 giorni.
Jade Biosciences (Nasdaq: JBIO), una compañía biotecnológica especializada en terapias para enfermedades autoinmunes, ha anunciado su participación en tres congresos sanitarios que se celebrarán en septiembre de 2025.
La empresa asistirá al Cantor Global Healthcare Conference (3-5 de septiembre), al Stifel Virtual Immunology and Inflammation Forum (15-16 de septiembre) y al 11th Annual World Medical Innovation Forum (15-17 de septiembre). La dirección realizará charlas informales (fireside chats), participará en un panel sobre inmunología y mantendrá reuniones individuales con inversores.
Los webcasts de las fireside chats de Cantor y Stifel estarán disponibles en la web de Jade con reproducción accesible durante 90 días.
Jade Biosciences (Nasdaq: JBIO)는 자가면역 질환 치료제에 특화된 생명공학 기업으로, 2025년 9월에 열리는 세 건의 헬스케어 콘퍼런스에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 3–5일), Stifel Virtual Immunology and Inflammation Forum(9월 15–16일), 11th Annual World Medical Innovation Forum(9월 15–17일)에 참석할 예정입니다. 경영진은 파이어사이드 채팅(fireside chats)을 진행하고 면역학 관련 패널 토론에 참여하며 일대일 투자자 미팅도 주최합니다.
Cantor와 Stifel 파이어사이드 채팅의 웹캐스트는 Jade 웹사이트에서 90일간 다시보기로 제공됩니다.
Jade Biosciences (Nasdaq: JBIO), une société de biotechnologie spécialisée dans les traitements des maladies auto-immunes, a annoncé sa participation à trois conférences de santé prévues en septembre 2025.
La société participera au Cantor Global Healthcare Conference (3-5 septembre), au Stifel Virtual Immunology and Inflammation Forum (15-16 septembre) et au 11th Annual World Medical Innovation Forum (15-17 septembre). La direction animera des « fireside chats », prendra part à une table ronde sur l'immunologie et organisera des rencontres individuelles avec des investisseurs.
Les webcasts des fireside chats de Cantor et Stifel seront disponibles sur le site de Jade avec un accès en replay pendant 90 jours.
Jade Biosciences (Nasdaq: JBIO), ein Biotechnologieunternehmen, das sich auf Therapien für Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an drei Gesundheitskonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference (3.–5. September), dem Stifel Virtual Immunology and Inflammation Forum (15.–16. September) und dem 11th Annual World Medical Innovation Forum (15.–17. September) teilnehmen. Das Management wird Fireside-Chats abhalten, an einer Podiumsdiskussion zur Immunologie teilnehmen und Einzelgespräche mit Investoren führen.
Die Webcasts der Fireside-Chats von Cantor und Stifel werden auf der Jade-Website mit einer 90-tägigen Wiedergabemöglichkeit verfügbar sein.
- None.
- None.
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Cantor Global Healthcare Conference (September 3–5, 2025)
Fireside Chat: Tuesday, September 3 at 3:20 p.m. ET - Stifel Virtual Immunology and Inflammation Forum (September 15–16, 2025)
Fireside Chat: Tuesday, September 16 at 1:00 p.m. ET - 11th Annual World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham (September 15–17, 2025)
Panel: Immunology – Creating the Next Blockbuster in I&I, Tuesday, September 16 at 4:40 p.m. ET
Members of the Jade management team will host one-on-one investor meetings during the conferences.
A live webcast of the Cantor and Stifel fireside chats will be available on the Events & Presentations page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL and is being developed for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Forward-Looking Statements
Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the potential of Jade’s product candidates to become best-in-class therapies and their potential therapeutic uses. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that Jade may experience unanticipated difficulties or delays in the product development process; Jade’s product candidates may fail in development or may not receive required regulatory approvals, and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.
Jade Biosciences Contact
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
FAQ
When is Jade Biosciences (JBIO) presenting at the Cantor Global Healthcare Conference 2025?
What conferences will Jade Biosciences (JBIO) attend in September 2025?
How can investors access Jade Biosciences' (JBIO) conference presentations?
What is Jade Biosciences' (JBIO) focus area in biotechnology?
